Table1_The Emergence of Rice and Millet Farming in the Zang-Yi Corridor of Southwest China Dates Back to 5000 Years Ago.XLSX

The Zang-Yi Corridor is of pivotal significance for the interactions between northwest China, southwest China, and mainland Southeast Asia. It has been hypothesized that the formation of mixed farming in this region and its surrounding areas was based on multiple waves of crop dispersal, with foxtail millet and broomcorn millet arriving first from northwest China around 5,300 cal. BP and rice from middle Yangtze valley after 4,700 cal. BP. Based on the systematic sampling and direct dating conducted at the Guijiabao site, Sichuan Province, this study demonstrates that by no later than 5,000 cal. BP, mixed farming had already emerged in the south part of Zang-Yi corridor, which was much earlier than expected before. With this new evidence, it is argued that the transformation into farming in Southwest China was based on the dispersal of a crop package comprising foxtail millet, broomcorn millet, and rice instead of different waves of introduction. A further comparison of all archaeobotanical data in this region revealed that crop patterns varied significantly between different sites because of their diverse environmental conditions.</p

The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma

<div><p>The prognostic value of CD30 expression indiffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67overexpression(p<0.05). Patients with CD30 expression showed significantly poor overall and event-free survivalcompared with CD30 negative patients(p = 0.031 and 0.041, respectively), especially those with the high intermediate/high-risk international prognostic index (IPI)(p = 0.001 and 0.007, respectively). The prognostic value of CD30expression retained in DLBCL patients treated with eitherCHOP (cyclophosphamide, doxorubicin, vincristine,prednisone) or R-CHOP(rituximab+CHOP). The multivariate analysisrevealed that the expression of CD30 remained an unfavorable factor for both overall and event-free survival (p = 0.001 and 0.002, respectively).In conclusion, these data suggest that CD30 is expressed predominantly in Non-GCBDLBCL. The expression of CD30 implied poor outcomein DLBCL patientstreated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest.</p></div

Supplementary Table S3 from Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression

Target UTR fragment sequences cloned in pMIR-REPORT-Luc vector (Addgene Cambridge, MA).</p

Supplementary Table S2 from Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression

Antibodies used for Western blotting and FACS.</p

Supplementary Figure S2 from Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression

5TGM1 cells stably overexpressing miR-342 and miR-363 were established by lentiviral vector transduction.</p

Supplementary Figure S4 from Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression

Runx2 knockdown by shRNA and miRNAs in 5TGM1 cells suppress PD-L1 mRNA levels.</p

Multivariate Cox regression analysis for survival.

<p>LDH, Lactate dehydrogenase; IPI,internationalprognosticindex; HR, hazard ratio</p><p>95%CI, 95confidence interval</p><p>Multivariate Cox regression analysis for survival.</p

Clinical characteristics of patients according to CD30 expression.

<p>LDH, Lactate dehydrogenase; BM, bone marrow;IPI,internationalprognosticindex</p><p>COO, cell of origin;GCB,germinal center B-cell like.</p><p>Clinical characteristics of patients according to CD30 expression.</p

Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS) according to the expression of CD30 and IPI.

<p>OS (A) and EFS (B) for high intermediate/high IPI risk patients (IPI = 3–5) with and without CD30 expression; OS (C) and EFS (D) for low/ low intermediate risk IPIpatients (IPI = 0–2)with and without CD30 expression.</p

Supplementary Figure S3 from Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression

Assessment of the number of PD-1+ and Tim-3+ CD8+ T cells from a population of gated CD3+ CD8+ T cells and of the number of IFN-γ+ CD3+ T cells from total CD3+ T cells.</p